|
Development of an anti-PSA IgE to treat prostate cancer
|
1R41CA137881-01
|
$158,851
|
|
SCHULTES, BIRGIT
|
ADVANCED IMMUNE THERAPEUTICS, INC.
|
|
Multiplexing Cancer Sample Preparation: Indirect Immunomagnetic Enrichment
|
5R43CA132049-02
|
$144,634
|
|
PAMULA, VAMSEE
|
ADVANCED LIQUID LOGIC
|
|
Nanoliter Lab-on-a-Chip for Rapid Parallel Immunoassays
|
5R44CA114993-03
|
$250,000
|
|
PAMULA, VAMSEE
|
ADVANCED LIQUID LOGIC
|
|
Experimental Models for Testing Novel Targets for Pancreatic Cancer Cell Invasion
|
5R21CA124931-02
|
$200,970
|
|
MOUSA, SHAKER
|
ALBANY COLLEGE OF PHARMACY
|
|
New Approaches to Prevent or Treat Breast Cancer Metastases
|
5R21CA129470-03
|
$186,750
|
|
GRAVEKAMP, CLAUDIA
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
Pro & Anti-Inflammatory Cytokines in Colorectal Cancer
|
5R01CA122654-02
|
$625,384
|
|
HO, GLORIA
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
H/D Exchange Coupled to MS to Study Drug-Induced Change in Microtuble Structure
|
5R01CA124898-03
|
$315,400
|
|
HORWITZ, SUSAN
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
Determinants of Resistance to Erlotinib in NSCLC
|
5R01CA113630-04
|
$286,106
|
|
PEREZ-SOLER, ROMAN
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
HEPADNAVIRUS ASSOCIATED HEPATOCELLULAR CARCINOMA
|
5R01CA037232-25
|
$498,055
|
$498,055
|
Rogler, Charles
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
VEGF Induced Signal Transduction
|
5R01CA086289-10
|
$301,024
|
|
SIBINGA, NICHOLAS
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
HPV & cervix neoplasia in a large, long-term HIV+ cohort
|
5R01CA085178-10
|
$692,565
|
|
STRICKLER, HOWARD
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
Skp2 in androgen-dependent proliferation of prostate cancer cells
|
1R01CA127901-01A2
|
$310,005
|
|
ZHU, LIANG
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
Dynamic MRI Scanner Operation Designed for Real-Time Applications
|
1R43CA137857-01
|
$96,721
|
|
Zientara, Gary
|
ALWAYSON MRI
|
|
MSI Faculty in the Field of Cancer
|
5R13CA076526-13
|
$78,120
|
|
FOTI, MARGARET
|
AMERICAN ASSOCIATION FOR CANCER RESEARCH
|
|
QUALITY RESEARCH IN RADIATION ONCOLOGY: ACR PCS
|
5R01CA065435-11
|
$564,543
|
|
WILSON, JESSE
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
American Psychosocial Oncology Society Annual Conference: Integrating Psychosocia
|
1R13CA138133-01
|
$20,000
|
|
BADGER, TERRY
|
AMERICAN PSYCHOSOCIAL ONCOLOGY SOCIETY
|
|
Primary Xenografts of Human Tissue as Surrogates of Cancer In Situ
|
1R43CA137737-01
|
$139,945
|
|
Zwick, Michael
|
ANDROBIOSYS, INC.
|
|
CellWell?: A microdevice for single cell analysis
|
5R21CA133551-03
|
$140,625
|
|
NETTIKADAN, SAJU
|
ASPERA CORPORATION
|
|
Engineering alpha fetoprotein and glypican-3 to develop hepatoma (HCC) vaccines
|
5R01CA168912-04
|
$320,588
|
$320,588
|
HE, YUKAI
|
AUGUSTA UNIVERSITY
|
|
TREM-1 and Its Implications to Cancer
|
5R01CA172230-04
|
$315,400
|
$315,400
|
HORUZSKO, ANATOLIJ
|
AUGUSTA UNIVERSITY
|
|
Role of heat shock transcription factor HSF1 in tumoroginesis
|
5R01CA062130-22
|
$556,510
|
$556,510
|
MIVECHI, NAHID
|
AUGUSTA UNIVERSITY
|
|
Development of cell-free DNA assays for HCC screening and liquid biopsy
|
5R01CA202769-02
|
$472,981
|
$472,981
|
SU, YING-HSIU
|
BARUCH S. BLUMBERG INSTITUTE
|
|
Effect of True Puff Profile Replication on Machine-Generated Smoke Constituents
|
1R21CA133893-01A1
|
$260,429
|
|
Gordon, Sydney
|
BATTELLE CENTERS/PUB HLTH RES & EVALUATN
|
|
A Proteomics Platform for Quantitative, Ultra-High Throughput, and Ultra-Sensitiv
|
5R33CA126191-03
|
$644,185
|
|
SMITH, RICHARD
|
BATTELLE PACIFIC NORTHWEST LABORATORIES
|
|
Role of NCoR in Antiandrogen Resistance in Prostate Cancer
|
5R21CA129265-02
|
$172,688
|
|
AGOULNIK, IRINA
|
BAYLOR COLLEGE OF MEDICINE
|
|
Breast cancer response markers to a dual HER1/2 blocker
|
5R01CA112305-05
|
$252,236
|
|
CHANG, JENNY
|
BAYLOR COLLEGE OF MEDICINE
|
|
Oncogenic Function of a P53-Induced Phosphatase
|
5R01CA100420-07
|
$266,843
|
|
Donehower, Lawrence
|
BAYLOR COLLEGE OF MEDICINE
|
|
A New Lab Based Algorithm for HCC Surveillance in Patients with Cirrhosis
|
5R01CA190776-03
|
$636,729
|
$636,729
|
EL-SERAG, HASHEM
|
BAYLOR COLLEGE OF MEDICINE
|
|
Enhancing T Cell Therapy of Cancer
|
5P01CA094237-07
|
$1,961,712
|
|
Heslop, Helen
|
BAYLOR COLLEGE OF MEDICINE
|
|
PROGENITOR CELLS AND ONCOGENE TARGETS IN BREAST CANCER
|
5R01CA113869-05
|
$280,899
|
|
LI, YI
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-11S1
|
$118,333
|
$3,550
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-11S2
|
$118,875
|
$3,566
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-11S3
|
$122,250
|
$3,668
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-11S4
|
$250,002
|
$7,500
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
5P30CA125123-11
|
$3,253,119
|
$97,594
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Hormonal Regulation of Breast Cancer
|
5R37CA016303-34
|
$781,755
|
|
Rosen, Jeffrey
|
BAYLOR COLLEGE OF MEDICINE
|
|
De facto Target of Histone Deacetylase Inhibitors
|
1R21CA215591-01
|
$172,369
|
$172,369
|
SUN, ZHENG
|
BAYLOR COLLEGE OF MEDICINE
|
|
Role of AIB3 in Mammary Gland and Breast Cancer
|
5R01CA119689-05
|
$280,899
|
|
XU, JIANMING
|
BAYLOR COLLEGE OF MEDICINE
|
|
Mitotic Catastrophe and the Mitotic Exit DNA Damage Checkpoint
|
5R01CA116097-04
|
$258,530
|
|
ZHANG, PUMIN
|
BAYLOR COLLEGE OF MEDICINE
|
|
MiRNAs in hepatocellular carcinoma development and treatment
|
2R01CA139158-06A1
|
$410,875
|
$410,875
|
HUANG, WENDONG
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Cancer Center Support Grant
|
3P30CA033572-34S1
|
$73,297
|
$1,466
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Cancer Center Support Grant
|
3P30CA033572-34S2
|
$124,999
|
$2,500
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Cancer Center Support Grant
|
5P30CA033572-34
|
$2,446,682
|
$48,934
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Modulating systemic pro-oncogenic effects of focal image-guided tumor ablation
|
5R01CA197081-02
|
$474,276
|
$161,254
|
AHMED, MUNEEB
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Targeting AR-NCoR Interaction in Prostate Cancer
|
5R01CA111803-03
|
$323,000
|
|
BALK, STEVEN
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
A Platform for Cancer Biomarker Validation: Image Fusion Using NIR Fluorescence
|
1R01CA134493-01A1
|
$745,852
|
|
FRANGIONI, JOHN
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
NIR Fluorescent SLN Mapping for Breast Cancer
|
5R21CA130297-02
|
$382,500
|
|
FRANGIONI, JOHN
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Oncogene-Induced Evasion from Apoptosis
|
5R01CA105306-05
|
$318,352
|
|
KHOSRAVI-FAR, ROYA
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
X-RAR alpha proteins: Molecualr Pathogenesis of Acute Promyelocytic Leukemia
|
5R37CA071692-13
|
$348,711
|
|
PANDOLFI, PIER PAOLO
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Rectifying defects in tumor vasculature to improve chemo- and radiation therapies
|
5R01CA129339-02
|
$352,750
|
|
SENGER, DONALD
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
Total relevant funding to Liver Cancer for this search: $81,909,198
|